The long-term objective of this project is to further our understanding of the physiological role of dopamine D1 and D2 receptors in normal CNS function and in the functional pathologies associated with schizophrenia and other mental health disorders. Evidence put forth by a number of investigators suggests that the overactivation of dopaminergic synaptic transmission may be important in the pathophysiology of schizophrenia. The precise relation of dopamine overactivation to schizophrenia, however, remaines vague. The present series of studies seeks to bridge this gap by investigating the consequences of overactivated dopamine systems on brain development and function by genetic manipulation of dopamine receptors, and by identifying the consequences of expression of mutant dopamine receptors in transgenic animals. In brief, these studies seek (a) to create constitutively active mutants of dopamine D1 and D2 receptors and to identify their pharmacological and biochemical characteristics, (b) to introduce selected constitutively active D1 and D2 receptor mutants into transgenic mice, (c) to characterize developmental abnormalities in animals with overactivated dopamine systems, and (d) to identify behavioral abnormalities in mice with constitutively active dopamine receptors. The studies will enhance our understanding of D1 and D2 receptors at the molecular level, lead to a better understanding of the action mechanisms for dopamine receptors, and may lead to the development of improved pharmacotherapies for dopamine system malfunctions. These studies will also lead to a better understanding of the developmental and functional consequences of dopamine overactivation and should provide us with some fundamental information pertaining to the relation of dopamine neurotransmission malfunctions with the development of the behavioral malfunctions underlying complex mental health disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29MH057889-02
Application #
2891049
Study Section
Molecular, Cellular, and Developmental Neurobiology Review Committee (MCDN)
Program Officer
Winsky, Lois M
Project Start
1998-07-01
Project End
2003-06-30
Budget Start
1999-07-01
Budget End
2000-06-30
Support Year
2
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of California Irvine
Department
Pharmacology
Type
Schools of Medicine
DUNS #
161202122
City
Irvine
State
CA
Country
United States
Zip Code
92697
Li, Ming; Li, Chuanyu; Weingarten, Paul et al. (2002) Association of dopamine D(3) receptors with actin-binding protein 280 (ABP-280). Biochem Pharmacol 63:859-63
Bermak, Jason C; Li, Ming; Bullock, Clayton et al. (2002) Interaction of gamma-COP with a transport motif in the D1 receptor C-terminus. Eur J Cell Biol 81:77-85
Bermak, J C; Zhou, Q Y (2001) Accessory proteins in the biogenesis of G protein-coupled receptors. Mol Interv 1:282-7
Weingarten, P; Zhou, Q Y (2001) Protection of intracellular dopamine cytotoxicity by dopamine disposition and metabolism factors. J Neurochem 77:776-85
Weingarten, P; Bermak, J; Zhou, Q Y (2001) Evidence for non-oxidative dopamine cytotoxicity: potent activation of NF-kappa B and lack of protection by anti-oxidants. J Neurochem 76:1794-804
Li, M; Bermak, J C; Wang, Z W et al. (2000) Modulation of dopamine D(2) receptor signaling by actin-binding protein (ABP-280). Mol Pharmacol 57:446-52